6^th Euro Cardiology Congress

Cardiovascular Pharmacology and Pharmacotherapy

Heart and cardiovascular disorders are the leading causes of hospitalization and death in the United States and around the world. Because of the vast potential market for these treatments, the pharmaceutical industry has prioritized the development of new therapeutic agents for cardiac disorders. A portion of these newer drugs are occasionally used in the practice of cardiovascular anesthesiology. This article examines the current developments in cardiovascular solutions connected with act of heart anesthetic cardiovascular pharmacology, focusing on the impact of diverse types of drugs on cardiovascular system regulation. It will include both cutting-edge drugs and recent advancements in understanding of more established treatments.

Understanding a new medication's component of activity allows anesthetists to incorporate it into their clinical practice. The research of critical components and pathways involved in heart rate generation and vascular management will reveal novel targets for atomic mediation in heart disorders. In the future, the age of small atoms will enable the investigation of such components and pathways to increase our understanding of fundamental science or pathology, as well as to spotlight new potentially useful leads and so attract the attention of industry.

Some of the significant research in cardiac pharmacology: Development of novel anti-inflammatory drugs for atherosclerosis; Ion channel reconstitution studies; Endothelial-vascular smooth muscle signaling; inotropic mechanisms; Development of novel anti-ischemic agents; Cellular mechanisms of pace making and arrhythmogenesis; Pathway biology of the cardiovascular system; drug-induced cardio toxicity mechanism.